Home  »  News   »  IOVA’s Market Whiplash: -13.85% YTD Decline,...

IOVA’s Market Whiplash: -13.85% YTD Decline, -20.22% Plunge in 30 Days

The stock price’s performance over the year has been unpredictable, resulting in a mix of pessimistic and optimistic outlooks among investors. The metric has seen a significant loss of -13.85% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -16.84%. Over the past 30 days, the price of IOVA has leaped by -20.22%. And in the last five days, it has fallen by -7.48%.

The stock of Iovance Biotherapeutics Inc. (IOVA) is currently priced at $5.51. In the last session, the stock climbed significantly, topping out at $5.48 after opening at $5.48. The day’s lowest price was $4.41 before the stock closed at $4.64.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Iovance Biotherapeutics Inc. experienced a somewhat shaky performance in the stock market. The company’s stock reached a 1-year high of $11.88 on 09/16/22, while the lowest price for the same period was registered at $4.41 on 09/14/23.

52-week price history of IOVA Stock

Examining the 52-week high and low prices can provide valuable insights into a stock’s current status and future performance. Iovance Biotherapeutics Inc.’s current trading price is -53.66% away from its 52-week high, while its distance from the 52-week low is 24.83%. The stock’s price range during this time has been between $4.41 and $11.88. The trading volume for the Healthcare sector company’s shares reached about 32.59 million for the day, which was higher than the average daily volume of 5.08 million over the last three months.

Market Capitalization vs. Financial Performance: A Comparative Study

Iovance Biotherapeutics Inc. (IOVA) has experienced a quarterly decline of -36.28% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.33B and boasts a workforce of 503 employees.

Iovance Biotherapeutics Inc.: Analysts’ Ratings Unveiled

As of right now, 11 analysts are rating Iovance Biotherapeutics Inc. as a BUY, 2 of the polled analysts branded the stock as an OVERWEIGHT, 2 analysts are recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.

Combining Moving Average and Trading Volume Data for Better Market Insight

Based on Barchart.com data, the company’s moving average over the 100-day period was 7.20, with a change in price of -0.27. Similarly, Iovance Biotherapeutics Inc. recorded 5,706,255 in trading volume during the last 100 days, posting a change of -4.74%.

IOVA’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look

The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for IOVA stands at 0.00. Similarly, the long-term debt-to-equity ratio is also 0.00.

IOVA Stock Stochastic Average

Today’s raw stochastic average for Iovance Biotherapeutics Inc. over the last 50 days is 23.16%.This indicates a decrease from the raw stochastic average of the past 20 days, which was 48.11%. Moreover, the company’s Stochastic %K and %D values for the last 20 days were 20.14% and 12.11%, respectively.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts